KNBIF (Kane Biotech) Additional Paid-In Capital: $6.14 Mil(As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kane Biotech Additional Paid-In Capital?

Kane Biotech KNBIF Additional Paid-In Capital is $6.14 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.


Kane Biotech's quarterly additional paid-in capital declined from Sep. 2025 ($6.17 Mil) to Dec. 2025 ($6.10 Mil) but then increased from Dec. 2025 ($6.10 Mil) to Mar. 2026 ($6.14 Mil).

Kane Biotech's annual additional paid-in capital increased from Dec. 2023 ($5.78 Mil) to Dec. 2024 ($5.84 Mil) and increased from Dec. 2024 ($5.84 Mil) to Dec. 2025 ($6.10 Mil).

Kane Biotech Additional Paid-In Capital Related Terms

Kane Biotech Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Additional Paid-In Capital Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.30 5.48 5.78 5.84 6.10

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 6.35 6.17 6.10 6.14

Kane Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $6.14 Mil mean?
Kane Biotech (KNBIF) has a Additional Paid-In Capital of $6.14 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Additional Paid-In Capital too high?
Kane Biotech's current Additional Paid-In Capital is $6.14 Mil.
How does Kane Biotech's Additional Paid-In Capital compare to VRTX and REGN?
Kane Biotech's Additional Paid-In Capital of $6.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Kane Biotech and its competitors. Kane Biotech's current Additional Paid-In Capital is $6.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Additional Paid-In Capital of $6.14 Mil. The current Additional Paid-In Capital is $6.14 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Additional Paid-In Capital is $6.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.